Epstein Secrets

.62 1.71 NA NN 196.1 11311 51013 510.6 (11391 13.11 et» 0331 lab il laTii 13541 Ot01 22595 3.5 DU 23.7 41501 O.% I17.1) (1611 Laine 91.4711.1 11374.2 51.761.1 51./C0.9 6123 5200 5010 6431 4436 1151.2 I.101.1 1.175.5 1145 oto 104 5730 1959 149.7 55/6 (433.1 134

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

.62 1.71 NA NN 196.1 11311 51013 510.6 (11391 13.11 et» 0331 lab il laTii 13541 Ot01 22595 3.5 DU 23.7 41501 O.% I17.1) (1611 Laine 91.4711.1 11374.2 51.761.1 51./C0.9 6123 5200 5010 6431 4436 1151.2 I.101.1 1.175.5 1145 oto 104 5730 1959 149.7 55/6 (433.1 134

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th

.62 1.71 NA NN 196.1 11311 51013 510.6 (11391 13.11 et» 0331 lab il laTii 13541 Ot01 22595 3.5 DU 23.7 41501 O.% I17.1) (1611 Laine 91.4711.1 11374.2 51.761.1 51./C0.9 6123 5200 5010 6431 4436 1151.2 I.101.1 1.175.5 1145 oto 104 5730 1959 149.7 55/6 (433.1 134

et, 3 ni floor San Francisco, CA 94103 Dear Mr. Tamaru: We have completed our analysis of the fair market value of the common equity of AliphCom ("Aliph" or the "Company") on a per share basis (the "Subject Interest") as of June 20, 2011 (the "Valuation Date"). We understand that our valuation of th